

## Editorial



# New Insight to the Pathogenetic Mechanism of Kawasaki Disease (KD): the Relationship between Clinical Diversity and Genetic Heterogeneity

Byung Won Yoo , MD<sup>1,2</sup>

<sup>1</sup>Department of Clinical Pharmacology, Clinical Trial Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

<sup>2</sup>Division of Pediatric Cardiology, Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea

## OPEN ACCESS

**Received:** Oct 10, 2018

**Accepted:** Nov 4, 2018

### Correspondence to

**Byung Won Yoo, MD**

Department of Clinical Pharmacology, Clinical Trial Center, Severance Hospital, Yonsei University College of Medicine, 50-1, Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.  
Email: bwyoo@yuhs.ac

Copyright © 2019. The Korean Society of Cardiology

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

### ORCID iDs

Byung Won Yoo   
<https://orcid.org/0000-0001-6895-1484>

### Conflict of Interest

The author has no financial conflicts of interest.

The contents of the report are the author's own views and do not necessarily reflect the views of the *Korean Circulation Journal*.

► See the article "Assessment of the Clinical Heterogeneity of Kawasaki Disease Using Genetic Variants of *BLK* and *FCGR2A*" in volume 49 on page 99.

Kawasaki disease (KD) or Kawasaki syndrome, an acute systemic vasculitis mainly developed in children younger than 5 years of age, may causes serious, life-threatening, cardiac sequelae including coronary artery aneurysm (CAA). Unfortunately, the disease-specific diagnostic tool of KD is lacking to date, and it has been a major obstacle to detect and treat the patients at the early stage and to prevent coronary artery lesions.

The cause of KD is largely unknown, but one of the most remarkable findings in its epidemiology is the distinct racial and familial tendency. Compared to the Western, the incidence rate in East Asian is 10 times higher.<sup>1)</sup> Also, from the data at Hawaii in 1996–2006, the incidence rate of white children was 13.7 per 100,000 children under 5 years old while that of Japanese children was 210.5, which is almost the same as that in mainland Japan. These data, which show very dramatic ethnic dominant pattern in KD, indicate that the different incidences between Western and East Asian are not caused by environmental or geographical factors, but by genetic disparity among ethnicities.<sup>2)</sup> On the other hand, the incidence in the family was reported to be 1.4–2.1%, which was more than 10-fold higher than in the general population, and especially with twins, reported 50- to 100-fold higher.<sup>3)</sup> These differences in racial and familial incidence strongly suggest that genetic factors play a major role in the development of KD.

Based on this background, to identify the genetic polymorphism associated with susceptibility to KD, numerous candidate genes related to immunologic or inflammatory reaction have been studied over 40 years. However, this kind of approaches failed to identify the definite disease loci because pathogenesis of KD is largely unknown. Therefore, several genome-wide association studies (GWASs) have been conducted worldwide (**Table 1**). Contrary to expectation, those results have not been consistent and the single-nucleotide polymorphisms that were found to be highly significant in one GWAS did not appear to be significant in other racial replication studies.<sup>4-6)</sup> The genetic factors associated with CAA, the most important long-term sequela of KD, have been studied in a few studies, but are not conclusive and have not yet been replicated in other study.

Table 1. GWASs for KD

Population	KD	Control	SNP	GWAS		Replication
				Gene	Function	
European <sup>13)</sup>	119	135	rs1463525	<i>NAALADL2</i>	-	-
			rs2106261	<i>ZFHX3</i>	-	-
			rs7193343*			
Taiwanese <sup>14)</sup>	250	446	rs1873668	<i>COPB2</i>	Regulation of T cell receptor signaling	-
			rs4243399			
			rs149481	<i>ERAP1</i>	M1 family of zinc metallopeptidases	-
			rs17113284	<i>IGHV</i>	Immunoglobulin heavy chain variable region gene	-
			rs8005468			
			rs10129255			
			rs2007467			
Korean <sup>15)</sup>	186	600	rs527409	<i>DAB1</i>	-	-
			rs7604693†	<i>PELI1</i>	Negative regulation of T cell R signaling	-
European <sup>16)</sup>	405	6,252	rs1801274	<i>FCGR2A</i>	Fc gamma receptor gene	+
			rs2233152	<i>MIA</i>	Growth inhibition on melanoma cells and neuroectodermal tumors	-
			rs10403040	<i>RAB4B</i>	Ras-related GTP-binding protein 4b gene (probably involved in vesicular traffic).	-
Japanese <sup>17)</sup>	428	3,379	rs2254546	<i>FAM167A-BLK</i>	Involve in B-cell receptor signal transduction	+
			rs2857151	<i>HLA-DQB2-HLA-DOB</i>	HLA region	-
			rs4813003	<i>CD40</i>	Increase translation efficiency of CD40	-
Taiwanese <sup>18)</sup>	622	1,107	rs2736340	<i>BLK</i>	Involve in B-cell receptor signal transduction	+
			rs1883832	<i>CD40</i>	Reduce functionally null isoform of CD40	-
			rs1569723			
Taiwanese <sup>19),‡</sup>	157 (11)	-	rs16921209†	<i>NEBL</i>	Binds to actin and involves in the assembly of the Z-disk of cardiac muscle	-
			rs7922552†			
			rs17076896†	<i>TUBA3C</i>	Tubulin is a major constituent of microtubules	-
Korean <sup>20),‡</sup>	140 (17)	-	rs17136627†	<i>KCNN2</i>	Calcium-activated potassium channel	-

Numbers in parenthesis indicate KD patients with CAA.

CAA = coronary artery aneurysm; GTP = guanosine-5'-triphosphate; GWAS = genome-wide association study; HLA = human leukocyte antigen; KD = Kawasaki disease; SNP = single nucleotide polymorphism.

\*rs7193343 was associated with protective effect on the risk for KD; †Risk loci associated with coronary artery lesion or aneurysm in patients with KD; ‡GWAS conducted to identify susceptibility genes associated with CAA in KD, the data from KD patients with CAA were compared to the data from KD patients without CAA.

The ethnic differences in the polymorphism of KD-associated gene may have a role in the discrepancy of those results. In fact, a meta-analysis study demonstrated that there is a significant association between the H131R polymorphism of *FCGR2A* gene and KD risk in Asians, but not in Caucasians.<sup>7)</sup> On the other hand, the gender difference was reported in the polymorphism of KD-associated gene. In a meta-analysis with 1,461 cases and 5,302 controls, a very strong association of KD with the *FCGR2A* gene was confirmed in males, but not in the females.<sup>8)</sup> From these findings, we could infer that the heterogeneous variation of KD-associated genes may contribute to the clinical and epidemiologic characteristics of KD.

Regarding the genetic heterogeneity in each KD patients, Sim et al.<sup>9)</sup> revealed a new finding that the genetic variations of related genes were associated with the diversity of clinical features in KD. KD is difficult to be diagnosed, because the number, timing, and duration of the clinical symptoms manifested in each patient are various, as to be referred to as Kawasaki syndrome. The authors provide a clue to this heterogeneity, analyzing the variations of *BLK* and *FCGR2A* gene that were identified in previous GWAS of KD patients and replicated in other population. In their results, the risk allele of *BLK* gene was strongly associated with complete KD in patients younger than 5 years, but not in patients with incomplete KD or older than 5 years old, and the risk allele of *FCGR2A* gene was strongly associated with only male patients younger than 1 year old. These findings suggest that the patients with the risk

allele of *BLK* could develop the KD at a younger age and fully manifest, showing typical KD features. Also, it could be suggested that the risk allele of *FCGR2A* encoding high-affinity Fc gamma receptor that binds to the immunoglobulin G (IgG), could affect the development of KD in infants, who show the rare incidence of KD with the hypothesis that passive transmission of maternal IgG has a preventive effect on KD.

The large sample size is a strong point of Sim' study (1,011 cases and 4,553 controls).<sup>9)</sup> However, their results showed some discrepancies with previous reports on the clinical feature of KD. Although treated with immunoglobulin therapy, subjects showed very high incidence of coronary artery lesions (20.8%), and the infant patients showed the similar incidences of incomplete KD (7.6%) and coronary artery complication (15.2%) as the patients older than 1 year. It has been recognized that infants with KD have a high incidence of incomplete KD (45–67%) and coronary artery complication (30.8–64%).<sup>10-12)</sup> These discrepancies could be attributed to the selection bias in the sample collection, and their effect on the results is not clearly understood. Nevertheless, Sim's work presents new insight into understanding the pathogenetic mechanism of KD. Although much understanding has been accumulated about the clinical diversity of KD, there has been a little research on the relationship between genetic heterogeneity and clinical features, except polymorphism related to the coronary artery complication. Therefore, their result is very interesting that heterogeneity of associated genes is related to clinical features. I expect that this study will lead to a better understanding for overcoming of KD by triggering further studies on the genetic heterogeneity of KD and its impact. Although it is still the tip of the iceberg that we have revealed about KD, we hope successive new attempts in this kind will reveal the secret nature of KD in near future.

## REFERENCES

1. Chang RK. Epidemiologic characteristics of children hospitalized for Kawasaki disease in California. *Pediatr Infect Dis J* 2002;21:1150-5.  
[PUBMED](#) | [CROSSREF](#)
2. Holman RC, Christensen KY, Belay ED, et al. Racial/ethnic differences in the incidence of Kawasaki syndrome among children in Hawaii. *Hawaii Med J* 2010;69:194-7.  
[PUBMED](#)
3. Fujita Y, Nakamura Y, Sakata K, et al. Kawasaki disease in families. *Pediatrics* 1989;84:666-9.  
[PUBMED](#)
4. Chi H, Huang FY, Chen MR, et al. ITPKC gene SNP rs28493229 and Kawasaki disease in Taiwanese children. *Hum Mol Genet* 2010;19:1147-51.  
[PUBMED](#) | [CROSSREF](#)
5. Peng Q, Chen CH, Wu Q, et al. Association study of a functional SNP rs28493229 of ITPKC gene and Kawasaki disease in a Chinese population. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi* 2011;28:644-8.  
[PUBMED](#)
6. Chatzikyriakidou A, Aidinidou L, Giannopoulos A, Papadopoulou-Legbelou K, Kalinderi K, Fidani L. Absence of association of *FCGR2A* gene polymorphism rs1801274 with Kawasaki disease in Greek patients. *Cardiol Young* 2015;25:681-3.  
[PUBMED](#) | [CROSSREF](#)
7. Lin L, Wang SY, Yang SB, Xiao FC. Association between the *FCGR2A* gene H131R polymorphism and risk of Kawasaki disease: a meta-analysis. *Genet Mol Res* 2015;14:6256-64.  
[PUBMED](#) | [CROSSREF](#)
8. Kwon YC, Kim JJ, Yun SW, et al. Male-specific association of the *FCGR2A* His167Arg polymorphism with Kawasaki disease. *PLoS One* 2017;12:e0184248.  
[PUBMED](#) | [CROSSREF](#)

9. Sim BK, Park HI, Kim JJ, et al. Assessment of the clinical heterogeneity of Kawasaki disease using genetic variants of *BLK* and *FCGR2A*. *Korean Circ J* 2019;49:99-108.  
[CROSSREF](#)
10. Joffe A, Kabani A, Jadavji T. Atypical and complicated Kawasaki disease in infants. Do we need criteria? *West J Med* 1995;162:322-7.  
[PUBMED](#)
11. No SJ, Kim DO, Choi KM, Eun LY. Do predictors of incomplete Kawasaki disease exist for infants? *Pediatr Cardiol* 2013;34:286-90.  
[PUBMED](#) | [CROSSREF](#)
12. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis and Kawasaki disease, council on cardiovascular disease in the young, American Heart Association. *Circulation* 2004;110:2747-71.  
[PUBMED](#) | [CROSSREF](#)
13. Burgner D, Davila S, Breunis WB, et al. A genome-wide association study identifies novel and functionally related susceptibility loci for Kawasaki disease. *PLoS Genet* 2009;5:e1000319.  
[PUBMED](#) | [CROSSREF](#)
14. Tsai FJ, Lee YC, Chang JS, et al. Identification of novel susceptibility loci for Kawasaki disease in a Han Chinese population by a genome-wide association study. *PLoS One* 2011;6:e16853.  
[PUBMED](#) | [CROSSREF](#)
15. Kim JJ, Hong YM, Sohn S, et al. A genome-wide association analysis reveals 1p31 and 2p13.3 as susceptibility loci for Kawasaki disease. *Hum Genet* 2011;129:487-95.  
[PUBMED](#) | [CROSSREF](#)
16. Khor CC, Davila S, Breunis WB, et al. Genome-wide association study identifies *FCGR2A* as a susceptibility locus for Kawasaki disease. *Nat Genet* 2011;43:1241-6.  
[PUBMED](#) | [CROSSREF](#)
17. Onouchi Y, Ozaki K, Burns JC, et al. A genome-wide association study identifies three new risk loci for Kawasaki disease. *Nat Genet* 2012;44:517-21.  
[PUBMED](#) | [CROSSREF](#)
18. Lee YC, Kuo HC, Chang JS, et al. Two new susceptibility loci for Kawasaki disease identified through genome-wide association analysis. *Nat Genet* 2012;44:522-5.  
[PUBMED](#) | [CROSSREF](#)
19. Kuo HC, Li SC, Guo MM, et al. Genome-wide association study identifies novel susceptibility genes associated with coronary artery aneurysm formation in Kawasaki disease. *PLoS One* 2016;11:e0154943.  
[PUBMED](#) | [CROSSREF](#)
20. Kim JJ, Park YM, Yoon D, et al. Identification of *KCNN2* as a susceptibility locus for coronary artery aneurysms in Kawasaki disease using genome-wide association analysis. *J Hum Genet* 2013;58:521-5.  
[PUBMED](#) | [CROSSREF](#)